Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,949.00    -78.00 (-2.58%)
Bid:
2,942.00
Ask:
2,946.00
Spread: 4.00 (0.136%)
Market Cap: £4.11b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

29 Jul 2013 07:00

RNS Number : 2528K
Croda International PLC
29 July 2013
 



29 July 2013

 

CRODA INTERNATIONAL PLC

 

Acquisition in China increases emerging market presence and strengthens Performance Technologies business

 

Croda International Plc ("Croda" or "the Group") announces that it has received Chinese regulatory approval to acquire a 65% equity interest in Sichuan Sipo Chemical Co. Ltd ("Sipo"), a non-listed natural speciality chemicals manufacturer based in Mianyang City, Sichuan Province, China. Completion of the transaction is subject to customary closing conditions which are expected to be fulfilled within the next few weeks.

 

The majority stake will be acquired from Sichuan Forever Holding Co. Ltd and certain individual shareholders for a total consideration of £38.2m*, including £8.0m* of debt, subject to working capital, net cash and fixed asset adjustments. Sichuan Forever Holding Co. Ltd will continue as the minority shareholder retaining a 35% equity interest in Sipo.

 

Sipo was established in 1993 and has approximately 300 employees. Sipo makes speciality derivatives from natural raw materials and its products include primary amides, novel fatty acids and speciality esters. In 2012 the business reported a turnover of £28.0m and EBITDA of £3.1m. A state of the art, well invested production facility, custom built in 2011, will provide additional capacity from the outset and increase Croda's proximity to customers in the region, strengthening its existing operations across China and the Group's overall position in Asia. Sipo will also consolidate Croda's global leadership in fatty acid amides and add new technology that will enable the Group to expand its portfolio across a number of its core markets.

 

Apart from a small number of by-products, all of Sipo's products will be sold through the Croda global sales network. Croda's initial focus is to grow sales from its Performance Technologies business to the Polymer Additives and Lubricants sectors, with further opportunities in new markets expected to follow in due course.

 

Steve Foots, Chief Executive of Croda, commented:

 

"This is a significant step forward in our strategy to increase Croda's presence in fast growing and emerging markets. Sipo's manufacturing capabilities together with our marketing expertise and sales force infrastructure are an exciting combination. We will have a stronger platform in niche markets and renewable technologies which will allow us to develop our customer base and drive sales growth in Asia. Our broader footprint in China will also enable us to be more responsive to customer needs in this important region."

 

For further information please contact:

 

Steve Foots, Group Chief Executive

Tel: 01405 860 551

Sean Christie, Group Finance Director

Charles Armitstead / Rosie Oddy, Pendomer Communications

Tel: 020 3603 5224

 

*purchase consideration of RMB361.6m and debt of RMB75.6m at an estimated exchange rate of RMB9.45/£.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQRFMMTMBATBMJ
Date   Source Headline
10th Oct 20243:39 pmRNSDirector/PDMR Shareholding
13th Sep 202410:07 amRNSDirector/PDMR Shareholding
11th Sep 20242:52 pmRNSDirector/PDMR Shareholding
13th Aug 20241:51 pmRNSDirector/PDMR Shareholding
30th Jul 20241:49 pmRNSDirector/PDMR Shareholding - Replacement
30th Jul 20241:40 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSResults for the six months ended 30 June 2024
12th Jul 202411:10 amRNSDirector Declaration
11th Jul 20242:21 pmRNSDirector/PDMR Shareholding
1st Jul 20247:00 amRNSCroda appoints Chief Financial Officer
25th Jun 202410:00 amRNSDirector/PDMR Shareholding
25th Jun 20247:00 amRNSDirectorate Change
13th Jun 20249:46 amRNSHolding(s) in Company
12th Jun 20249:01 amRNSDirector/PDMR Shareholding
11th Jun 20242:12 pmRNSDirector/PDMR Shareholding
30th May 20243:27 pmRNSDirector/PDMR Shareholding
30th May 20242:33 pmRNSDirector/PDMR Shareholding
13th May 20242:16 pmRNSDirector/PDMR Shareholding
2nd May 20249:27 amRNSDirector/PDMR Shareholding
1st May 202412:18 pmRNSDirector/PDMR Shareholding
25th Apr 202410:01 amRNSResult of AGM
24th Apr 20247:00 amRNSFirst quarter 2024 sales update
11th Apr 20242:11 pmRNSDirector/PDMR Shareholding
8th Apr 202410:54 amRNSDirector/PDMR Shareholding
8th Apr 202410:23 amRNSDirector/PDMR Shareholding
28th Mar 20249:17 amRNSDirector/PDMR Shareholding
26th Mar 20244:19 pmRNSDirector/PDMR Shareholding
26th Mar 20244:10 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:09 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSDirector/PDMR Shareholding
26th Mar 20244:06 pmRNSDirector/PDMR Shareholding
26th Mar 20244:04 pmRNSDirector/PDMR Shareholding
15th Mar 20249:32 amRNSAnnual Financial Report
12th Mar 20242:49 pmRNSDirector/PDMR Shareholding
7th Mar 20243:03 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSResults for the year ended 31 December 2023
13th Feb 20243:35 pmRNSDirector/PDMR Shareholding
9th Feb 20243:28 pmRNSHolding(s) in Company
18th Jan 20241:33 pmRNSHolding(s) in Company
11th Jan 20243:17 pmRNSDirector/PDMR Shareholding
18th Dec 20237:00 amRNSDirectorate Change
12th Dec 20233:08 pmRNSDirector/PDMR Shareholding
11th Dec 202311:39 amRNSDirector Declaration
29th Nov 20234:54 pmRNSHolding(s) in Company
28th Nov 20239:35 amRNSDirector/PDMR Shareholding
24th Nov 202311:33 amRNSHolding(s) in Company
14th Nov 20239:40 amRNSDirector/PDMR Shareholding
19th Oct 202311:19 amRNSHolding(s) in Company
19th Oct 202310:34 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.